Aleksander Lenert,Jenna Thomason,Melanie H Smith,Helena Abodeely,Sandy D Hong,Courtney E Kremer,Petar S Lenert,T Shawn Sato,Sandra Hansmann,Melissa Oliver,Yongdong Dan Zhao,Jonathan Templin,Mary Vaughan-Sarrazin,Robyn Domsic,Daniel H Solomon,Polly J Ferguson
{"title":"Quality of Life in Adult SAPHO and Chronic Nonbacterial Osteomyelitis and Comparison to Chronic Rheumatic and Inflammatory Diseases.","authors":"Aleksander Lenert,Jenna Thomason,Melanie H Smith,Helena Abodeely,Sandy D Hong,Courtney E Kremer,Petar S Lenert,T Shawn Sato,Sandra Hansmann,Melissa Oliver,Yongdong Dan Zhao,Jonathan Templin,Mary Vaughan-Sarrazin,Robyn Domsic,Daniel H Solomon,Polly J Ferguson","doi":"10.3899/jrheum.2025-0414","DOIUrl":null,"url":null,"abstract":"OBJECTIVE\r\nThe health effects of SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO) have not been well studied. We assessed health-related quality life (HRQOL) in adults with SAPHO-CNO and performed a review of EQ-5D outcomes amongst similar chronic rheumatic and inflammatory diseases.\r\n\r\nMETHODS\r\nWe enrolled patients in the first US-based SAPHO-CNO prospective registry and assessed their HRQOL using the EQ-5D index and EQ-5D VAS. A focused scoping review was performed of EQ-5D related outcomes amongst disease cohorts with phenotypic similarities to SAPHO-CNO.\r\n\r\nRESULTS\r\nIn the 138 SAPHO-CNO participants, mean age (standard deviation) was 37.7 (15.0) years with a mean disease duration of 6.4 (6.2) years. All subjects had musculoskeletal involvement (44% having spine involvement) and 48% had skin involvement. Mean EQ-5D-5L index value was 0.75 (0.16) and mean EQ-VAS was 63.0 (21.0). Most patients were impacted by pain/discomfort (86%), difficulty in carrying out usual activities (65%) and anxiety/depression (54%); over one-third reported problems in all five EQ-5D domains. These SAPHO-CNO adults had similarly reduced EQ-5D and VAS values, and similar high proportion of perceived problems, as other inflammatory disease cohorts.\r\n\r\nCONCLUSION\r\nThe HRQOL among adults with SAPHO-CNO is low, with more than half of patients experiencing an impact in perceived pain, performing usual activities, and feelings of anxiety or depression. Future therapies should target the multi-dimensional nature of SAPHO-CNO, targeting HRQOL as a major outcome.","PeriodicalId":501812,"journal":{"name":"The Journal of Rheumatology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3899/jrheum.2025-0414","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
OBJECTIVE
The health effects of SAPHO syndrome and chronic nonbacterial osteomyelitis (CNO) have not been well studied. We assessed health-related quality life (HRQOL) in adults with SAPHO-CNO and performed a review of EQ-5D outcomes amongst similar chronic rheumatic and inflammatory diseases.
METHODS
We enrolled patients in the first US-based SAPHO-CNO prospective registry and assessed their HRQOL using the EQ-5D index and EQ-5D VAS. A focused scoping review was performed of EQ-5D related outcomes amongst disease cohorts with phenotypic similarities to SAPHO-CNO.
RESULTS
In the 138 SAPHO-CNO participants, mean age (standard deviation) was 37.7 (15.0) years with a mean disease duration of 6.4 (6.2) years. All subjects had musculoskeletal involvement (44% having spine involvement) and 48% had skin involvement. Mean EQ-5D-5L index value was 0.75 (0.16) and mean EQ-VAS was 63.0 (21.0). Most patients were impacted by pain/discomfort (86%), difficulty in carrying out usual activities (65%) and anxiety/depression (54%); over one-third reported problems in all five EQ-5D domains. These SAPHO-CNO adults had similarly reduced EQ-5D and VAS values, and similar high proportion of perceived problems, as other inflammatory disease cohorts.
CONCLUSION
The HRQOL among adults with SAPHO-CNO is low, with more than half of patients experiencing an impact in perceived pain, performing usual activities, and feelings of anxiety or depression. Future therapies should target the multi-dimensional nature of SAPHO-CNO, targeting HRQOL as a major outcome.